Brind.

Prothena is testing its drug PRX012 in early symptomatic Alzheimer's Disease patients.

1 report, 1 independent Updated Aug 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Prothena (Ireland)

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Prothena (Ireland)
company in Dublin, Ireland

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 28Business WireProthena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program As previously communicated, Prothena plans to explore potential partnership interest to advance PRX01